Successful non-neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with a methotrexate, vincristine, and BCNU protocol (DEMOB)
1986; Wiley; Volume: 57; Issue: 1 Linguagem: Inglês
10.1002/1097-0142(19860101)57
ISSN1097-0142
AutoresIan J. Cohen, Ruth Vogel, Shoshana Matz, Raphael Weitz, Celia Mor, Sidi Stern, Rina Zaizov,
Tópico(s)Chemotherapy-induced cardiotoxicity and mitigation
ResumoCancerVolume 57, Issue 1 p. 6-11 ArticleFree Access Successful non-neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with a methotrexate, vincristine, and BCNU protocol (DEMOB) Ian J. Cohen Mb, ChB, Corresponding Author Ian J. Cohen Mb, ChB Sambur Center for Pediatric Hematology Oncology, Beilinson Medical Center, Petah Tiqva, and Tel Aviv University Sackler School of Medicine, IsraelSambur Center for Pediatric Hematology Oncology, Beilinson Medical Center, Petah Tiqva 49 100, Israel===Search for more papers by this authorRuth Vogel MD, Ruth Vogel MD Sambur Center for Pediatric Hematology Oncology, Beilinson Medical Center, Petah Tiqva, and Tel Aviv University Sackler School of Medicine, IsraelSearch for more papers by this authorShoshana Matz MD, Shoshana Matz MD Radiology, Beilinson Medical Center, Petah Tiqva, and Tel Aviv University Sackler School of Medicine, IsraelSearch for more papers by this authorRaphael Weitz MD, Raphael Weitz MD Pediatrics, Beilinson Medical Center, Petah Tiqva, and Tel Aviv University Sackler School of Medicine, IsraelSearch for more papers by this authorCelia Mor MD, Celia Mor MD Department of Pathology, Beilinson Medical Center, Petah Tiqva, and Tel Aviv University Sackler School of Medicine, IsraelSearch for more papers by this authorSidi Stern MSc, Sidi Stern MSc Department of Pathology, Beilinson Medical Center, Petah Tiqva, and Tel Aviv University Sackler School of Medicine, IsraelSearch for more papers by this authorRina Zaizov MD, Rina Zaizov MD Sambur Center for Pediatric Hematology Oncology, Beilinson Medical Center, Petah Tiqva, and Tel Aviv University Sackler School of Medicine, IsraelSearch for more papers by this author Ian J. Cohen Mb, ChB, Corresponding Author Ian J. Cohen Mb, ChB Sambur Center for Pediatric Hematology Oncology, Beilinson Medical Center, Petah Tiqva, and Tel Aviv University Sackler School of Medicine, IsraelSambur Center for Pediatric Hematology Oncology, Beilinson Medical Center, Petah Tiqva 49 100, Israel===Search for more papers by this authorRuth Vogel MD, Ruth Vogel MD Sambur Center for Pediatric Hematology Oncology, Beilinson Medical Center, Petah Tiqva, and Tel Aviv University Sackler School of Medicine, IsraelSearch for more papers by this authorShoshana Matz MD, Shoshana Matz MD Radiology, Beilinson Medical Center, Petah Tiqva, and Tel Aviv University Sackler School of Medicine, IsraelSearch for more papers by this authorRaphael Weitz MD, Raphael Weitz MD Pediatrics, Beilinson Medical Center, Petah Tiqva, and Tel Aviv University Sackler School of Medicine, IsraelSearch for more papers by this authorCelia Mor MD, Celia Mor MD Department of Pathology, Beilinson Medical Center, Petah Tiqva, and Tel Aviv University Sackler School of Medicine, IsraelSearch for more papers by this authorSidi Stern MSc, Sidi Stern MSc Department of Pathology, Beilinson Medical Center, Petah Tiqva, and Tel Aviv University Sackler School of Medicine, IsraelSearch for more papers by this authorRina Zaizov MD, Rina Zaizov MD Sambur Center for Pediatric Hematology Oncology, Beilinson Medical Center, Petah Tiqva, and Tel Aviv University Sackler School of Medicine, IsraelSearch for more papers by this author First published: 1 January 1986 https://doi.org/10.1002/1097-0142(19860101)57:1 3.0.CO;2-BCitations: 39AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract A 3.5-year-old boy with a multifocal primary lymphoma of the brain was treated successfully without neurotoxicity with a treatment regimen that did not include radiation. The protocol of Dexacort (dexamethasone), methotrexate, Oncovin (vincristine), and BCNU (carmustine) (DEMOB), which was developed with the use of MTX pharmocokinetic studies, was given over 7.5 months, and resulted in tumor disappearance on computerized tomography scans and marked improvement in clinical status. The patient remains in good health 3 years after diagnosis (March 1985). References 1 Taylor CR, Russell R, Lukes RJ, Davis RL. An immunohistological study of immunoglobulin content of primary central nervous system lymphomas. Cancer 1978; 41: 2197–2205. 2 Aronin PA, Mahaley MS Jr., Rudnick SA et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: An assessment of risk factors. N Engl J Med 1980; 303: 183–188. 3 Taylor CR. Immunoperoxidase techniques. Arch Pathol Lab Med 1978; 102: 113–121. 4 Mepam BL, Frater W, Mitchell BS. The use of proteolytic enzymes to improve immunoglobulin staining by the PAP technique. Histochem J 1979; 11: 345–357. 5 Myers CE, Lippman ME, Eliot HM. Competitive protein binding assay for methotrexate. Proc Natl Acad Sci USA 1975; 72: 3883–3886. 6 Burstein SD, Kernohan JW, Uchlein A. Neoplasms of the reticuloendothelial system of the brain. Cancer 1963; 16: 289–305. 7 Henry JH, Heffner RR, Dillard SH, Earle KM, Davis RL. Primary malignant lymphomas of the central nervous system. Cancer 1974; 1293–1302. 8 Littman P, Wang CC. Reticulum cell sarcoma of the brain. Cancer 1975; 35: 1412–1420. 9 Mendenhall NP, Thar TL, Agee DF et al. Primary lymphoma of the central nervous system. Cancer 1983; 52: 1993–2000. 10 Sagerman RH, Cassady JR, Chang CH. Radiation therapy for intracranial lymphoma. Radiology 1967; 88: 552–554. 11 Samuelsson SM, Werner I, Ponten J et al. Reticuloendothelial (perivascular) sarcoma of the brain. Acta Neurol Scand 1966; 42: 567–580. 12 Tubman DE, Frick MP, Hanto DW. Lymphoma after organ transplantation: Radiologic manifestations in the central nervous system, thorax and abdomen. Radiology 1983; 149: 625–631. 13 Penn I. The price of immunotherapy. Curr Probl Surg 1981; 681–751. 14 Perry GS, Spector BD, Schuman LM et al. The Wiskott Adrich syndrome in the United States and Canada 1892–1979. J Pediatr 1980; 97: 72–78. 15 Weingarten KL, Zimmerman RD, Leeds NE. Spontaneous regression of intracerebral lymphoma. Radiology 1983; 149: 721–724. 16 Herbst KD, Corder MP, Justice GR. Successful treatment with methotrexate of a multicentric lymphoma of the central nervous system. Cancer 1976; 38: 1476–1478. 17 Hryniuk WM, Bertino JR. Treatment of leukemia with large doses of methotrexate and folic acid: Clinical-biochemical correlates. J Clin Invest 1969; 48: 2140–2155. 18 Ervin T, Canellos GP. Successful treatment of recurrent primary central nervous system lymphoma with high dose methotrexate. Cancer 1980; 45: 1556–1557. 19 Abelson HT, Jufe DW, Skarin AT et al. Treatment of central nervous system tumors with methotrexate. Cancer Treat Rep 1981; (suppl 1) 65: 131, 137–140. 20 Munk J, Peyser E, Gruszkcewicz J. Radiation induced intracranial meningiomas. Clin Radiol 1969; 20: 90–94. 21 Jannoun L. Are cognitive and educational development affected by age at which prophylactic therapy is given in acute lymphoblastic leukemia? Arch Dis Child 1983; 58: 953. 22 Griffin TW, Rasey JS, Bleyer WA. The effect of photon irradiation on blood brain barrier permeability to methotrexate in mice. Cancer 1977; 40: 1109–1111. 23 Cohen IJ, Ratzhabi R, Kaplinski C, Zaizov R. Cerebrospinal fluid levels of methotrexate following various therapeutic regimes in children with malignancies (Abstr). International Pediatric Oncology Conference, Rome, Italy, October 21–24, 1981. 24 Meadows AT, Evans AE. Effects of chemotherapy on the central nervous system: A study of parenteral methotrexate in long term survivors of leukemia and lymphoma in childhood. Cancer 1976; 37: 1079. 25 Makulu DR, Smith EF, Berlino JR. Lack of dihydrofolate reductase activity in brain tissues of mammalian species: possible implications. J Neurochem 1973; 21: 241–245. 26 Pollock RJ, Kaufman S. Difolate reductase in present in brain. J Neurochem 1978; 30: 253–256. 27 Levitt M, Nixon PF, Pincus JH, Berlino JR. Transport characteristics of folates in cerebrospinal fluid: A study utilizing doubly labelled 5-methyltetrahydrofolate and 5-formyl tetrahydrofolate. J Clin Invest 1971; 50: 1301–1308. 28 Shapiro WR, Young DR, Mehta BM. Methotrexate distribution in cerebrospinal fluid after intravenous ventricular and lumbar injection. N Engl J Med 1975; 293: 161–166. 29 Mehta BM, Glass JP, Shapiro WR. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-ommaya administration in patients with meningeal carcinomatosis. Cancer Res 1983; 43: 436–438. 30 Bertino JR. Rescue techniques in cancer chemotherapy: Use of leucovorin and other rescue techniques after methotrexate treatment. Semin Oncol 1977; 4: 203–216. 31 Howell SB, Krishan A, Frei E III. Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate. Cancer Res 1979; 39: 1315–1320. 32 Allen JC, Rosen G, Mehta BM, Horten B. Leucoencephalopathy following high-dose methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 1980; 64: 1261–1273. 33 Abelson HT. Methotrexate and central nervous system toxicity. Cancer Treat Rep 1978; 62: 1999–2001. 34 Shapiro WR, Allen JC, Horten B. Chronic methotrexate toxicity to the central nervous system. Clin Bull 1980; 10: 49–52. Citing Literature Volume57, Issue11 January 1986Pages 6-11 ReferencesRelatedInformation
Referência(s)